Diasorin Inc.
Stillwater, MN Part of Diasorin S.P.A.
- UEI
- FGK2QR959BV5
- CAGE
- 1KF01
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Diasorin S.P.A., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
KN6PH2K51SJ6
-
- Cypress, CA KFFNMC55GHS5
- Austin, TX VLLHHV5E3AL1
-
-
Parent
KN6PH2K51SJ6
- SAM.gov registration date
- Physical address
- 1951 Northwestern Ave, Stillwater, MN 55082, USA
- Website
- diasorin.com
- Founded
- 2000
- Employees
- 1K-5K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $59,624 |
| FY2026 | $4,191,765 |
| FY2025 | $3,516,614 |
| FY2024 | $3,266,565 |
| FY2023 | $2,956,349 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $2,469,833 | |
| 2 | Defense Health Agency | $1,569,222 | |
| 3 | Department of Health and Human Services | $212,334 |
Contract vehicles
Expired vehicles (1)
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Luminex Corp | Austin, TX | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Abbott Nutrition | Lake Bluff, IL | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Abbott Molecular Inc. | Des Plaines, IL | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Roche Diagnostics Corporation | Indianapolis, IN | 325413 In-Vitro Diagnostic Substance Manufacturing |
| US Customer Operations | Brea, CA | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Diasorin Inc., a Minnesota-based subsidiary of Italian parent Diasorin S.P.A., manufactures and supplies chemiluminescence immunoassay analyzers, diagnostic reagents, consumables, and related laboratory services to federal healthcare agencies as a prime contractor across a 472-award portfolio with combined potential value of $133.4 million. The vendor competes exclusively on a full-and-open basis without socioeconomic set-asides, leveraging proprietary LIAISON XL and LIAISON XS analyzer platforms for infectious disease diagnostics including COVID-19, tuberculosis, varicella, cytomegalovirus, and latent tuberculosis screening via QuantiFERON assays.
Diasorin's customer concentration reflects a healthcare-focused federal footprint. The Defense Health Agency leads by potential value with 32 awards worth $19.1 million, followed by the Air Force Materiel Command ($16.5 million, 14 awards), CDC ($16 million, 15 awards), and the Department of Veterans Affairs across multiple Veterans Integrated Service Networks—with VISN 22 alone carrying 37 awards totaling $14.1 million. Combined, the top five customer organizations account for 55% of potential value. Award counts skew toward the VA system: VISN 22 (37 awards), Defense Health Agency (32), Army Medical Command (30), VISN 4 (24), and VISN 17 (22) collectively represent 145 awards, or 31% of the total portfolio. This bifurcation reflects both high-volume consumables orders from VA networks and larger-dollar equipment and reagent contracts with military medical treatment facilities.
Diasorin sits on multiple vehicle types anchoring federal procurement. The $10 million Critical Analyzers, Laboratory Federal Supply Schedule (FSS-66-III) with the VA generated 15 task orders worth $5.6 million in combined value through March 2030. Diasorin also holds a single-award BPA with Air Force Materiel Command at Wright-Patterson Air Force Base, established March 2021 at $250,000 ceiling, that has supported 18 BPA calls totaling $994 thousand for diagnostic test kits and reagents. Additional single-award IDIQs include a $1.75 million vehicle with VISN 9 (reagents, testing, and lease through September 2029), a $1.5 million VISN 20 IDIQ through July 2030 for laboratory tests, and a $750,000 VISN 23 indefinite delivery contract through September 2026. A Defense Health Agency IDIQ for LIAISON XL test kits and supplies carries a $540,000 ceiling through September 2030. Most recent vehicle wins include two BPAs awarded August 2026: VISN 4 at $1.45 million and VISN 2 at $2.3 million, both under the FSS-66-III Federal Supply Schedule for bacterial marker and infectious disease equipment and supplies.
Activity growth has been steady year over year, from 18 awards in 2022 to 31 in 2025, with 22 awards recorded in 2026 (year-to-date through October). Twenty-three awards with combined potential value of $4.7 million face ultimate completion within the next twenty-four months, representing meaningful recompete exposure. Award concentration by commodity reflects Diasorin's product mix: In-Vitro Diagnostic Substance Manufacturing (180 awards) and Analytical Laboratory Instrument Manufacturing (84 awards) dominate the NAICS breakdown, supported by PSC codes for In Vitro Diagnostic Substances (219 awards) and Laboratory Equipment and Supplies (92 awards).
Diasorin operates exclusively as a prime contractor with zero subcontract footprint across the portfolio—the vendor performs substantially all work in-house. Service Contract Inventory data, covering federal service contracts above the $150,000 reporting threshold, shows minimal SCI-reportable activity: $20 thousand invoiced in FY2024 across 0.1 FTEs, with all other fiscal years showing zero reportable service revenue. This reflects Diasorin's business model, which is product- and equipment-centric rather than services-intensive; SCI captures only service contracts and excludes goods, reagents, and consumables that make up the bulk of Diasorin's federal revenue. Government-paid hourly rates on the single SCI-reportable service contract ran $122.57 per hour with no subcontractor hours recorded. The vendor's corporate structure includes two named subsidiaries: Luminex Corp and Diasorin Molecular LLC, both foreign-owned manufacturers.
Quick answers
Is Diasorin Inc. registered in SAM.gov?
Yes. Diasorin Inc.'s SAM.gov registration is active through May 20, 2027.
Which contract vehicles does Diasorin Inc. hold?
Diasorin Inc. holds a place on 2 federal contract vehicles, including MAS.
How much has Diasorin Inc. received in federal contracts?
Federal contracts obligated $3,516,614 to Diasorin Inc. in fiscal year 2025 and $13,990,917 in fiscal years 2023 through 2027.
How does Diasorin Inc. rank among federal contractors?
Diasorin Inc.'s parent company, Diasorin S.P.A., ranked #10 in NAICS 325413, #18 in PSC 6550 and #59 in NAICS 3254 in FY2025.
What is Diasorin Inc.'s most recent federal award?
Diasorin Inc.'s most recent federal contract award is Liaison XL supplies and services (36C25527N0045), from Veterans Integrated Service Network 15 (VHA), on October 15, 2026.
On GovTribe
See Diasorin Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors